Mirati Therapeutics (NASDAQ:MRTX) Research Coverage Started at StockNews.com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Several other brokerages also recently issued reports on MRTX. Guggenheim lowered their price objective on shares of Mirati Therapeutics from $104.00 to […]
International Biotechnology Trust PLC grew its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 6.6% in the 2nd quarter, Holdings Channel reports. The firm owned 260,000 shares of the biotechnology company’s stock after acquiring an additional 16,000 shares during the quarter. Mirati Therapeutics accounts for about 2.9% of International Biotechnology Trust […]
Congress Asset Management Co. MA grew its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 1.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,460 shares of the biotechnology company’s stock after acquiring an additional 473 shares during the quarter. Congress […]
B. Riley downgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from a buy rating to a neutral rating in a research note published on Monday morning, Marketbeat Ratings reports. They currently have $60.00 price objective on the biotechnology company’s stock, down from their previous price objective of $65.00. Other research analysts also recently issued […]